Trial Profile
A Global, Multicenter, Three Arms, Open-label Randomized Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension Compared to Taxotere® (Docetaxel Injection Concentrate) in Triple-negative Breast Cancer Patients With Locally Advanced or Metastatic Breast Cancer After Failure to Prior Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Feb 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors Jina Pharmaceuticals
- 09 Feb 2023 Planned End Date changed from 31 May 2022 to 31 Jul 2024.
- 09 Feb 2023 Planned primary completion date changed from 31 Mar 2022 to 31 May 2024.
- 21 Sep 2018 New trial record